AR064501A1 - Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos - Google Patents
Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicosInfo
- Publication number
- AR064501A1 AR064501A1 ARP070105866A ARP070105866A AR064501A1 AR 064501 A1 AR064501 A1 AR 064501A1 AR P070105866 A ARP070105866 A AR P070105866A AR P070105866 A ARP070105866 A AR P070105866A AR 064501 A1 AR064501 A1 AR 064501A1
- Authority
- AR
- Argentina
- Prior art keywords
- antagonists
- app
- treatment
- neurological disorders
- same
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 4
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 abstract 9
- 101710187751 Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 abstract 9
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan métodos y composiciones que comprenden antagonistas del DR6 para su uso en el tratamiento de trastornos neurologicos, incluida la enfermedad de Alzheimer. Los antagonistas del DR6 incluyen anticuerpos anti-APP, anticuerpos anti-DR6, inmunoadhesinas del DR6 y variantes del DR6 (y proteínas de fusion de las mismas) que potencian el crecimiento, la regeneracion y la supervivencia de tejido o células neuronales. Reivindicacion 1: Un método para la inhibicion de la union del Receptor de muerte 6 (DR6) a la proteína precursora amiloide (APP) que suponen la exposicion del polipéptido del DR6 y/o del polipéptido de la APP a uno o más antagonistas del DR6 en condiciones en las que se inhibe la union del DR6 a la APP.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87152806P | 2006-12-22 | 2006-12-22 | |
| US90084807P | 2007-02-12 | 2007-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064501A1 true AR064501A1 (es) | 2009-04-08 |
Family
ID=39535220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105866A AR064501A1 (es) | 2006-12-22 | 2007-12-21 | Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100203044A1 (es) |
| EP (1) | EP2094732A2 (es) |
| JP (1) | JP2010514700A (es) |
| KR (1) | KR20090094854A (es) |
| AR (1) | AR064501A1 (es) |
| AU (1) | AU2007336770A1 (es) |
| BR (1) | BRPI0719459A2 (es) |
| CA (1) | CA2671903A1 (es) |
| CL (1) | CL2007003793A1 (es) |
| CO (1) | CO6210755A2 (es) |
| MX (1) | MX2009006685A (es) |
| NO (1) | NO20092741L (es) |
| NZ (1) | NZ577436A (es) |
| PE (1) | PE20081546A1 (es) |
| RU (1) | RU2009128039A (es) |
| SG (1) | SG177924A1 (es) |
| TW (1) | TW200844113A (es) |
| WO (1) | WO2008080045A2 (es) |
| ZA (1) | ZA201004219B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011005481A (es) * | 2008-11-25 | 2011-08-17 | Biogen Idec Inc | Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso. |
| TW201034684A (en) * | 2009-02-18 | 2010-10-01 | Genentech Inc | Method for inhibiting neurodegeneration |
| EP2498817A2 (en) * | 2009-11-12 | 2012-09-19 | F. Hoffmann-La Roche AG | A method of promoting dendritic spine density |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| MX359070B (es) | 2010-12-01 | 2018-09-13 | Alderbio Holdings Llc | Composiciones anti-ngf y uso de las mismas. |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US20120238465A1 (en) * | 2011-03-17 | 2012-09-20 | Joseph Audie | Drug screening target for alzheimer's disease and method of screening potential drugs |
| CN102708565A (zh) * | 2012-05-07 | 2012-10-03 | 深圳市贝尔信智能系统有限公司 | 一种前景检测的方法、装置和系统 |
| PL3058371T3 (pl) | 2013-10-14 | 2021-11-08 | Indiana University Research And Technology Corporation | Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd |
| EP3072527B1 (en) | 2013-11-20 | 2022-03-09 | National University Corporation Hokkaido University | Immunosuppressant |
| EP3116895A4 (en) * | 2014-03-12 | 2017-08-16 | Temple University Of The Commonwealth System Of Higher Education | Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide |
| ES2955841T3 (es) | 2015-03-16 | 2023-12-07 | Regeneron Pharma | Célula de un roedor que presenta función de la neurona motora superior e inferior y percepción sensorial disminuidas |
| CN106794222B (zh) * | 2015-03-26 | 2021-08-24 | 苏州澳宗生物科技有限公司 | 使用p75ecd和/或p75诊断或治疗神经障碍的方法 |
| CA3023088A1 (en) * | 2016-05-06 | 2017-11-09 | Abbvie Stemcentrx Llc | Novel anti-tnfrsf21 antibodies and methods of use |
| KR102351126B1 (ko) * | 2019-12-03 | 2022-01-13 | 재단법인대구경북과학기술원 | App 및 mdga1 단백질 상호작용 억제제를 포함하는 약학적 조성물 및 이를 이용한 스크리닝 방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3702789A1 (de) * | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
| DK0939121T4 (da) * | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
| CA2079880A1 (en) * | 1990-04-24 | 1991-10-25 | William E. Van Nostrand | Purification, detection and methods of use of protease nexin-2 |
| US5213962A (en) * | 1990-04-24 | 1993-05-25 | The Regents Of The University Of California | Purification, detection and methods of use of protease Nexin-2 |
| US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| CA2123211C (en) * | 1991-11-12 | 2008-09-16 | Colin L. Masters | A method for assaying and treating alzheimer's disease |
| CA2086165A1 (en) * | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US6013476A (en) * | 1997-04-02 | 2000-01-11 | Smithkline Beecham Corporation | DNA encoding tumor necrosis related receptor TR7 |
| US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
| US6949358B1 (en) * | 1997-06-11 | 2005-09-27 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor TR9 |
| US7378507B2 (en) * | 1997-09-18 | 2008-05-27 | Genentech, Inc. | PRO217 polypeptides |
| US6194151B1 (en) * | 1997-09-26 | 2001-02-27 | Millenium Pharmaceuticals, Inc. | Molecules of the TNF receptor superfamily and uses therefor |
| FR2778858B1 (fr) * | 1998-05-20 | 2000-06-16 | Oreal | Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique |
| US6916907B1 (en) * | 1998-10-23 | 2005-07-12 | Curagen Corporation | Nucleic acids encoding osteoprotegern-like proteins and methods of using same |
| US6423494B1 (en) * | 1999-03-25 | 2002-07-23 | Millennium Pharmaceuticals, Inc. | DR6 and uses thereof |
| AT5874U1 (de) * | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| US7241570B2 (en) * | 2001-03-23 | 2007-07-10 | University Of Utah Research Foundation | Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use |
| CN100488982C (zh) * | 2001-11-02 | 2009-05-20 | 迪尔基因国际有限公司 | 与β-淀粉样蛋白结合并引起蛋白质构象转变的单克隆抗体的制备方法 |
| WO2003040183A2 (en) * | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
| AU2002359459A1 (en) * | 2001-12-17 | 2003-06-30 | Eli Lilly And Company | Treating b-cell mediated diseases by modulating dr6 activity |
| EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| EP1447093A1 (en) | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
| AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| ES2301280A1 (es) * | 2005-05-16 | 2008-06-16 | Fina Biotech S.L.U. | Metodo para diagnosticar la enfermedad de alzheimer. |
| US20100099609A1 (en) * | 2008-07-28 | 2010-04-22 | Buck Institute For Age Research | eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE |
| EP2498817A2 (en) * | 2009-11-12 | 2012-09-19 | F. Hoffmann-La Roche AG | A method of promoting dendritic spine density |
-
2007
- 2007-12-21 JP JP2009543252A patent/JP2010514700A/ja active Pending
- 2007-12-21 NZ NZ577436A patent/NZ577436A/en not_active IP Right Cessation
- 2007-12-21 BR BRPI0719459-5A2A patent/BRPI0719459A2/pt not_active IP Right Cessation
- 2007-12-21 US US12/520,044 patent/US20100203044A1/en not_active Abandoned
- 2007-12-21 WO PCT/US2007/088521 patent/WO2008080045A2/en not_active Ceased
- 2007-12-21 EP EP07869737A patent/EP2094732A2/en not_active Withdrawn
- 2007-12-21 KR KR1020097015353A patent/KR20090094854A/ko not_active Withdrawn
- 2007-12-21 CA CA002671903A patent/CA2671903A1/en not_active Abandoned
- 2007-12-21 RU RU2009128039/10A patent/RU2009128039A/ru not_active Application Discontinuation
- 2007-12-21 SG SG2011096492A patent/SG177924A1/en unknown
- 2007-12-21 CL CL200703793A patent/CL2007003793A1/es unknown
- 2007-12-21 MX MX2009006685A patent/MX2009006685A/es not_active Application Discontinuation
- 2007-12-21 AR ARP070105866A patent/AR064501A1/es not_active Application Discontinuation
- 2007-12-21 AU AU2007336770A patent/AU2007336770A1/en not_active Abandoned
- 2007-12-21 TW TW096149573A patent/TW200844113A/zh unknown
-
2008
- 2008-01-02 PE PE2008000033A patent/PE20081546A1/es not_active Application Discontinuation
-
2009
- 2009-07-16 CO CO09074363A patent/CO6210755A2/es not_active Application Discontinuation
- 2009-07-21 NO NO20092741A patent/NO20092741L/no not_active Application Discontinuation
-
2010
- 2010-06-14 ZA ZA2010/04219A patent/ZA201004219B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2671903A1 (en) | 2008-07-03 |
| WO2008080045A3 (en) | 2008-09-12 |
| US20100203044A1 (en) | 2010-08-12 |
| CO6210755A2 (es) | 2010-10-20 |
| BRPI0719459A2 (pt) | 2014-02-04 |
| RU2009128039A (ru) | 2011-01-27 |
| AU2007336770A1 (en) | 2008-07-03 |
| TW200844113A (en) | 2008-11-16 |
| CL2007003793A1 (es) | 2008-07-25 |
| WO2008080045A2 (en) | 2008-07-03 |
| EP2094732A2 (en) | 2009-09-02 |
| MX2009006685A (es) | 2009-07-27 |
| SG177924A1 (en) | 2012-02-28 |
| JP2010514700A (ja) | 2010-05-06 |
| ZA201004219B (en) | 2013-02-27 |
| NO20092741L (no) | 2009-09-21 |
| KR20090094854A (ko) | 2009-09-08 |
| NZ577436A (en) | 2012-05-25 |
| PE20081546A1 (es) | 2008-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064501A1 (es) | Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos | |
| CO6341640A2 (es) | \\\"tratamiento de enfermedad autoinmunitaria e inflamatoria\\\" | |
| CR20150016A (es) | Anticuerpo monoclonal | |
| SV2008002511A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| AR036401A1 (es) | Incremento de la cantidad de celulas madre neuronales inducido por prolactina. | |
| NZ592516A (en) | Antibodies to il-6 and use thereof | |
| CL2008001826A1 (es) | Metodos y composicion para el tratamiento de enfermedades alergicas anticuerpo anti-receptor de linfopoyetina estromal timica humana (tslp) o porcion de enlace de antigeno del mismo; polinucleotido que lo codifica; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o trastorno inflamatorio en un sujeto | |
| CY1111714T1 (el) | Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf). | |
| EA200701211A1 (ru) | Полипептиды, которые связываются с br3, и их применение | |
| CR20120415A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
| EP1951319A4 (en) | Chimeric immunoreceptor useful in treating human cancers | |
| EP1916964A4 (en) | IMPLANTS AND METHODS FOR THE REPAIR, REPLACEMENT AND TREATMENT OF JOINT DISEASES | |
| BRPI0511111A (pt) | compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários | |
| EA200900202A1 (ru) | Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование | |
| ATE542823T1 (de) | 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen | |
| WO2005112981A3 (en) | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells | |
| ATE395924T1 (de) | Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen | |
| DE602006015387D1 (de) | Beta-2 Adrenoceptor Agonisten zur Behandlung von Bindegewebserkrankungen der Haut | |
| ATE515268T1 (de) | Verwendung von op-1 zur behandlung von knorpeldefekten | |
| WO2008083169A3 (en) | Compositions and methods for the treatment of immunologic disorders | |
| GT200600115A (es) | Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal | |
| Smagin et al. | Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism | |
| UY29077A1 (es) | Amidas sustituidas de ácido tienopirrolcarboxílico, amidas del ácido pirrolotiazolcarboxílico y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon) | |
| WO2008061209A3 (en) | G protein coupled receptors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |